Navigation Links
Exagen Diagnostics Enters Into Exclusive Agreement With EndoChoice
Date:2/16/2010

ALBUQUERQUE, N.M., Feb. 16 /PRNewswire/ -- Exagen Diagnostics, Inc., a molecular diagnostics laboratory that discovers, develops and markets proprietary genomic tests, today announced an exclusive sales and marketing agreement with EndoChoice, Inc. to promote its diagnostic services to gastroenterologists throughout the United States.

Under the agreement, EndoChoice's experienced, gastroenterology-focused sales force will introduce Exagen's proprietary gene expression tests for the diagnosis of Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS).  Exagen developed these molecular tests through its discovery engine, Coperna®, which identified "gene activity signatures" associated with IBD and IBS.

Scott Glenn, Exagen's CEO said, "We are excited about the opportunity of partnering with EndoChoice to accelerate the adoption of our technology by gastroenterologists.  Our eXaIBD™ and eXaIBS™ tests have both high sensitivity and accuracy, helping to identify IBD and IBS from other diseases, avoiding an extensive series of exclusionary testing."

"EndoChoice is focused on satisfying the unmet needs of GI professionals by delivering innovative, best-in-class products and services," said Mark Gilreath, EndoChoice's CEO.  "We are pleased to offer Exagen's proprietary eXaIBD™ and eXaIBS™ tests because they provide a superior diagnostic tool to assist gastroenterologists and improve patient care."

About Exagen Diagnostics, Inc.

Exagen Diagnostics is the emerging leader in laboratory-discovered and developed genomic tests specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. Using Coperna®, the company's proprietary, algorithm-driven computational tool and search engine that runs on high-performance computational clusters, it combines the ability to process massive amounts of data contained in genomic datasets with intelligent, rapid search methods. Coperna's targeted and precise discovery model has no conventional equivalent in the molecular diagnostics industry as it can identify relevant marker sets with superior sensitivity and specificity relative to markers identified via traditional analytical methods. For more information, please visit www.exagen.com.

About EndoChoice, Inc.

EndoChoice delivers innovative solutions to professionals in gastrointestinal endoscopy with its diverse portfolio of high-quality diagnostics, equipment, devices, supplies and services.   The company strives to cleverly exceed its customers' expectations through its nationwide sales force, exemplary customer care, superior products and easy online ordering.  For more information, visit www.endochoice.com.

SOURCE Exagen Diagnostics, Inc.

RELATED LINKS
http://www.exagen.com
http://www.endochoice.com

'/>"/>

SOURCE Exagen Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Scott Glenn Joins Exagen Diagnostics as Chairman and CEO
2. AstraZeneca and Dako Sign Agreement to Develop Companion Diagnostics for Cancer Treatments
3. Sword Diagnostics Announces Availability of Proprietary Detection Technology for Ultrasensitive Immunoassays.
4. Inverness Medical Innovations Offers to Acquire Standard Diagnostics
5. Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics
6. Fujirebio Diagnostics Named Life Sciences Company of the Year
7. U.S. Patent Office Issues Sword Diagnostics Patent for Highly Sensitive Immunodetection Technology
8. Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation
9. Roche Diagnostics Opens State-of-the-Art Training Center in California
10. Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition
11. Reportlinker Adds Molecular Diagnostics - A World Market Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 ViewRay, Inc. (Nasdaq: ... federal institution supporting research in Germany ... patient treatments at the University Clinic Heidelberg as part ... The MRIdian Linac program will be headed by Medical ... heads radiation oncology at the German Cancer Research Center ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... New Therapeutic Option to Address Motor Symptoms and ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... Fabrizio Stocchi , European Neurological Review,2016;11(Suppl. 2): 2-15, ...
(Date:1/19/2017)... , Jan. 18, 2017  ViewRay, Inc. (Nasdaq: ... first and only clinical MRI-guided radiation therapy system, announced ... of approximately $26.1 million through a private placement ... Management led the financing and was joined by ... LLC and Kearny Venture Partners, and an additional ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh has posted a new publication this ... generation is a time like no other and society needs to understand the only way ... does not want to sound like an old bible beater because religion has a bad ...
(Date:1/20/2017)... ... 2017 , ... Doctor C LLC, a company based out of Arizona that ... continue the marketing and distribution of its product, The Right C. , The Right ... absorption than traditional vitamin C supplements. At the trade show, Doctor C had the ...
(Date:1/20/2017)... ... 20, 2017 , ... Lice Troopers, the lice removal company based in South ... since the holiday season. , β€œIt happens every year around this time,” says ... taking photos, which is the head-to-head gateway that lice need to spread.” , As ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... International ... of nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in ... bodybuilder and nutritional scientist who was determined to create a line of products that ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have a ...
Breaking Medicine News(10 mins):